Turing Medical’s Bullsai Identify Platform Receives the US FDA’s Clearance for Precision Brain Mapping
Shots:
- The US FDA has granted 510(k) clearance to the company’s Bullsai Identify platform for precision brain mapping
- Developed as an automated mapping solution, Bullsai offers personalized data to enable neuromodulation therapy planning for neurological disorders like Parkinson's disease & essential tremor. It also generates insights on patient-specific brain locations for improved treatment planning
- The platform employs advanced imaging and algorithms to create patient-specific brain maps to find optimal targets for neuromodulation therapies such as DBS & FUS. The goal is to improve outcomes, reduce off-target effects & shorten recovery times
Ref: Turing Medical | Image: Turing Medical
Related News:- GENETIKA+ and NeuroSense Commence Precision Medicine Collaboration with the Ongoing P-II Trial in Alzheimer’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
